LONDON, Aug. 27 /PRNewswire/ -- Following the successful acquisition of Drug Development Solutions ('DDS') in February, Chiltern, a leading contract research organization, announced today that it has fully integrated its two early Phase units into a single operation branded as Chiltern Early Phase.
Chiltern Early Phase is providing high quality early phase services for the pharmaceutical industry via its two well established units in Slough (just outside of London) and Dundee, Scotland. With a total of 72 high care beds, 42 of which are based at Ninewells Hospital in Dundee, Chiltern Early Phase can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in First Time in Man, drug photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies.
Glenn Kerkhof, Chiltern's Chief Executive Officer said, "When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision and provide a truly expert Early Phase service at reasonable cost."
Dr Brian Sanderson, Medical Director of Chiltern Early Phase commented, "I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."
Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad
therapeutic range for a wide variety of clients. Chiltern employs over
1,250 people located in 23 off
Copyright©2008 PR Newswire.
All rights reserved